Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 207-975-3 | CAS number: 503-74-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Isovaleric acid is rapidly absorbed and removed from the blood due to rapid metabolic degradation to 3-HMG-CoA, acetoacetate and acetyl-CoA. The pathway is the same as for the amino acid leucine, i.e. isovaleric acid does physiologically occur in the intermediary metabolisms . Bioaccumulation does not occur.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 100
- Absorption rate - inhalation (%):
- 100
Additional information
Isovaleric acid is rapidly absorbed from the GI tract, and it is rapidly removed (50% within 11 minutes; Al-Bassam and Sherrat, 1981)) from the blood after iv injection into mice. Metabolism occurs primarily in the liver on the same pathway as the ketogenic amino acid leucine and via the ß-pathways for fatty acids, i.e. it does also naturally occur as a metabolite of the amino acid leucine. First, 3-Hydroxymethyl-glutaryl-CoA (HMG-CoA) is formed which is then further degraded to acetoacetate and acetyl-CoA. Alternatively, HMG-CoA and acetyl-CoA may be used as precursors of fatty acids and cholesterol (HSDB, 2003; Semino, 1998). Thus, isovaleric acid is utilised in the intermediary metabolism and there is no bioaccumulation potential.
Read Across
The view above is supported by observations with a closely related substance, isobutyric acid. The metabolic fate of isobutyric acid (IBA) was investigated by oral (gavage) administration of radiolabelled [1-14C]isobutyric acid to groups of 4 male CD rats at doses of 4, 40, and 400 mg/kg bw and to 4 female CD rats at 400 mg/kg bw. IBA was eliminated rapidly in the breath of the dosed animals as expired 14CO2. At 4 hr 67 to 83% and at 48 hr 85 to 90% of the dose was eliminated in the breath. There were no differences between sexes. Urinary radioactivity averaged 3.5% of the dose with about 2/3 of the radioactivity present as urea. Faecal radioactivity was less than 1% of the dose. Isobutyric acid disappeared rapidly from the plasma of rats dosed by gavage with 400 mg/kg bw. Plasma levels peaked between 0.5 and 1 hr (11.4 ± 2.4 µg/ml), decreased to3.3 µg/mL at 1 hr, and were below the limit of detection at 4 hr (DiVicenzo, 1979).
Justification of Read Across to isobutric acid
The metabolism of isovaleric acid is considered to be similar to that of isobutyric acid. Differences are, however, expected regarding the velocity and the extent of elimination as CO2in the breath because the isovaleric acid is metabolised by a pathway other than ß-oxidation due to the 3-methyl group, and because 3-hydroxymethylglutaryl-CoA may be used as precursor of cholesterol.
Conclusions from Read Across
However, quantitative conclusions can be drawn as follows: Isovaleric acid is expected to be rapidly absorbed from the gastro-intestinal tract with peak plasma levels after 0.5 to 1 hour after dosing, followed by rapid and complete elimination due to rapid metabolism, and return to normal plasma levels within few hours after dosing. Bioaccumulation does not occur.
Absorption rates
In the absence of pharmacokinetic studies on isovaleric acid, the absorption rate for the free acid is considered to be 100% for the oral, inhalation and dermal routes of exposure, based on the provisions in the respective chapters contained in the Guidance document R7 (2008; Fig 7.12 -5 etc.).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.